FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2174408096> ?p ?o ?g. }

• W2174408096 abstract "OBJECTIVE: The objective of this selective EBM review is to determine whether or not treatment with onabotulinumtoxinA improves the quality of life in patients with urinary incontinence not adequately controlled with anticholinergics. STUDY DESIGN: Review of three English language, randomized controlled trials published in 2013. DATA SOURCES: Randomized, double-blind, controlled clinical trials comparing onabotulinumtoxinA intradetrusor injections with saline placebo. All articles were found using PubMed. OUTCOMES MEASURED: Each of the three trials assessed the patient’s quality of life after treatment with onabotulinumtoxinA using the following assessment tools: Incontinence Quality of Life Questionnaire (I-QOL), Modified Overactive Bladder Patient Satisfaction with Treatment Questionnaire (OAB-PSTQ), King’s Health Questionnaire (KHQ), Patient Global Assessment (PGA), and Treatment Benefit Scale. RESULTS: Both the Chancellor et al. and the Sussman et al. studies found a statistically significant improvement in the change from baseline in the I-QOL and OAB-PSTQ for the patients who received onabotulinumtoxinA compared to placebo (p value < 0.001). Nitti et al. demonstrated an improvement range of 19.6 to 23.9 ± SD change from baseline in the I-QOL score for the onabotulinumtoxinA treatment group. 60.8% of the experimental group in Nitti et al. reported a positive treatment response after onabotulinumtoxinA while only 29.2% of placebo patients reported this response (p value < 0.001). Sussman et al established an inverse correlation between I-QOL total scores and UI frequency with a Pearson’s correlation coefficient of -0.508 at week 12 establishing that decreased frequency in urinary incontinence events are associated with improved quality of life. CONCLUSIONS: Based on the three trials, onabotulinumtoxinA does improve quality of life in patients with urinary incontinence not adequately controlled with anticholinergics by improving patient satisfaction with treatment, urinary incontinence symptoms, and healthcare related quality of life." @default.
• W2174408096 created "2016-06-24" @default.
• W2174408096 creator A5082950944 @default.
• W2174408096 date "2015-01-01" @default.
• W2174408096 modified "2023-09-26" @default.
• W2174408096 title "Does Treatment With OnabotulinumtoxinA Improve the Quality of Life in Patients With Urinary Incontinence Not Adequately Controlled With Anticholinergics" @default.
• W2174408096 cites W2041926096 @default.
• W2174408096 cites W2074581746 @default.
• W2174408096 cites W2147101940 @default.
• W2174408096 cites W94668587 @default.
• W2174408096 hasPublicationYear "2015" @default.
• W2174408096 type Work @default.
• W2174408096 sameAs 2174408096 @default.
• W2174408096 citedByCount "0" @default.
• W2174408096 crossrefType "journal-article" @default.
• W2174408096 hasAuthorship W2174408096A5082950944 @default.
• W2174408096 hasConcept C126322002 @default.
• W2174408096 hasConcept C126894567 @default.
• W2174408096 hasConcept C142724271 @default.
• W2174408096 hasConcept C159110408 @default.
• W2174408096 hasConcept C168563851 @default.
• W2174408096 hasConcept C1862650 @default.
• W2174408096 hasConcept C204787440 @default.
• W2174408096 hasConcept C27081682 @default.
• W2174408096 hasConcept C2778531004 @default.
• W2174408096 hasConcept C2778941218 @default.
• W2174408096 hasConcept C2779951463 @default.
• W2174408096 hasConcept C535046627 @default.
• W2174408096 hasConcept C71924100 @default.
• W2174408096 hasConcept C77411442 @default.
• W2174408096 hasConceptScore W2174408096C126322002 @default.
• W2174408096 hasConceptScore W2174408096C126894567 @default.
• W2174408096 hasConceptScore W2174408096C142724271 @default.
• W2174408096 hasConceptScore W2174408096C159110408 @default.
• W2174408096 hasConceptScore W2174408096C168563851 @default.
• W2174408096 hasConceptScore W2174408096C1862650 @default.
• W2174408096 hasConceptScore W2174408096C204787440 @default.
• W2174408096 hasConceptScore W2174408096C27081682 @default.
• W2174408096 hasConceptScore W2174408096C2778531004 @default.
• W2174408096 hasConceptScore W2174408096C2778941218 @default.
• W2174408096 hasConceptScore W2174408096C2779951463 @default.
• W2174408096 hasConceptScore W2174408096C535046627 @default.
• W2174408096 hasConceptScore W2174408096C71924100 @default.
• W2174408096 hasConceptScore W2174408096C77411442 @default.
• W2174408096 hasLocation W21744080961 @default.
• W2174408096 hasOpenAccess W2174408096 @default.
• W2174408096 hasPrimaryLocation W21744080961 @default.
• W2174408096 hasRelatedWork W1991604490 @default.
• W2174408096 hasRelatedWork W2006302964 @default.
• W2174408096 hasRelatedWork W2017101410 @default.
• W2174408096 hasRelatedWork W2074581746 @default.
• W2174408096 hasRelatedWork W2147101940 @default.
• W2174408096 hasRelatedWork W2179396169 @default.
• W2174408096 hasRelatedWork W2328680462 @default.
• W2174408096 hasRelatedWork W2332614769 @default.
• W2174408096 hasRelatedWork W2584069643 @default.
• W2174408096 hasRelatedWork W2586421621 @default.
• W2174408096 hasRelatedWork W2613298658 @default.
• W2174408096 hasRelatedWork W2614933017 @default.
• W2174408096 hasRelatedWork W2796167486 @default.
• W2174408096 hasRelatedWork W2801402309 @default.
• W2174408096 hasRelatedWork W2897865165 @default.
• W2174408096 hasRelatedWork W2922911071 @default.
• W2174408096 hasRelatedWork W3044776901 @default.
• W2174408096 hasRelatedWork W3154837796 @default.
• W2174408096 hasRelatedWork W3196193023 @default.
• W2174408096 hasRelatedWork W3198007398 @default.
• W2174408096 isParatext "false" @default.
• W2174408096 isRetracted "false" @default.
• W2174408096 magId "2174408096" @default.
• W2174408096 workType "article" @default.